Skip to Content

'
Homer A. Macapinlac, MD, FACNM

Present Title & Affiliation

Primary Appointment

James E. Anderson Distinguished Professor of Nuclear Medicine, Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Department Chair, Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1400 Pressler
Unit Number: 1483
Houston, TX 77030
Room Number: FCT16.6024
The University of Texas MD Anderson Cancer Center
P.O. Box 301402
Houston, TX 77230-1402
Phone: 1-800-392-1611

Education & Training

Degree-Granting Education

1983 University of the East, Ramon Magsaysay Memorial Medical Center, Quezon City, Philippines, MD, Doctor of Medicine
1979 University of the Philippines, Quezon City, Philippines, BS, Biology

Postgraduate Training

7/1992-6/1994 Clinical Fellowship, Positron Emission Tomography and Nuclear Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, Steven M. Larson, M.D.
7/1991-6/1992 Chief Resident, Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, Steven M. Larson, M.D.
7/1989-6/1991 Resident, Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, Steven M. Larson, M.D.
7/1988-6/1989 Chief Resident, Anatomic and Surgical Pathology, New York Medical College, Metropolitan-Lincoln Hospitals, New York, NY, Victor Tchertkoff, MD
7/1987-6/1988 Clinical Residency, Anatomic and Surgical Pathology, New York Medical College, Metropolitan-Lincoln Hospitals, New York, NY, Victor Tchertkoff, MD
7/1985-6/1987 Research Fellowship, Nuclear Medicine & MRI, University of California School of Medicine, San Francisco, CA, Robert C. Brasch, M.D.
7/1984-6/1985 Clinical Internship, Family Medicine, Philippine Ministry of Health-Rural Health Practice Program, Quezon City, Philippines
7/1983-6/1984 Clinical Internship, University of the East, Ramon Magsaysay Memorial Medical Center, Quezon City, Philippines

Board Certifications

12/2022 Certification Board of Nuclear Cardiology
9/1991 American Board of Nuclear Medicine

Experience/Service

Consultantships

Expert Consultant, International Atomic Energy Agency, Vienna, Austria, 1/2000-present

Institutional Committee Activities

Member, CABI Executive Steering Committee, 3/2011-present
Member, CABI Research Operations Committee, 3/2011-present
Member, EDI CIPRIT Grant Internal Advisory Board, 2/2010-12/2010
Member, Medical Physics Task Force - Chair: Dr. Raymond Sawaya, 1/2010-3/2010
Member, Experimental Diagnostic Imaging Medical Director Search Committee, 2008-2010
Member, Search Committee for the Experimental Diagnostic Imaging Section of Cyclotron-Radiochemistry Chief, 2008-2010
Member, Plastic Surgery Policies & Procedures Task Force, 7/2007-6/2009
Member, CME Advisory Committee, 9/2006-8/2010
Member, MDACC/IGR Sister Institution Program, 2006-present
Member, PET/CT Q/A & Education, 9/2004-present
Member, Diagnostic Imaging Executive Committee, 2001-present

Honors and Awards

2011-2012 Best Doctors in America
2010-2011 Best Doctors in America
2009-2010 Best Doctors in America
2009 President's Distinguished Service Award, Society of Nuclear Medicine
2008-2011 Invited Lecturer, International Visiting Professor Program, Radiological Society of North America
2008 Most Outstanding Alumnus in Medical Research, UERM College of Medicine
2007 Top 50 Most Cited Articles in 2007, Journal of Clinical Oncology
2003 Outstanding Educator Award, UT M. D. Anderson Cancer Center
1994 Outstanding Manuscript Award, Journal of Nuclear Medicine
1993 Best Proffered Paper, Society of Nuclear Medicine
1992 Best Proffered Paper, Society of Nuclear Medicine
1991 Best Proffered Paper, Society of Nuclear Medicine
1991 Second Prize, Scientific Exhibit, Society of Nuclear Medicine

Professional Memberships

Academy of Molecular Imaging, Los Angeles, CA
Chair, Institute of Clinical PET, 2005-2006
Member, 2003-present
American Board of Radiology, Tucson, AZ
Member, Maintenance of Certification (MOC) Exam Team, 2007-present
American College of Nuclear Physicians
Member, 2003-present
American College of Radiology, Reston, VA
Member, 1/2009-present
Member, State Chapter, 1/2009-present
American College of Surgeons Oncology Group
Member, 2006-present
European Association of Nuclear Medicine
Member, 2005-present
Harris County Medical Society, Houston, TX
Member, 2007-present
International Association for the Study of Lung Cancer (IASLC), Aurora, CO
Member, 2006-present
National Comprehensive Cancer Network, Fort Washington, PA
Member, Clinical Utility of PET Task Force, 2008
National Institutes of Health, Washington, DC
Member, Clinical Center Radiology and Imaging Science Departmentĺs Nuclear Medicine Division Strategic Review Advisory Panel, 6/2013
Member, Special Emphasis Panel - Review Group 2009/10 NCI-H, 7/2009
Radiological Society of North America, Oak Brook, IL
Member, Annual Scientific Assembly Committee, 2004-2010
Society of Nuclear Medicine Molecular Imaging, Reston, VA
Member, PET COE Working Group Chairs, 2007-present
Member, Referring Physicians Working Group, 2007-present
Co-Chair, PET Utilization Task Force, 2007-2011
Member, Commission on Education, 2007-2009
Member, Commission on Health Practice, 2007-2009
Member, Committee on Councils & Centers, 2007-2009
President, PET Center of Excellence, 2007-2009
Member, House of Delegates, 2006-present
Member, PET Center of Excellence, 2005-present
Texas Medical Association, Austin, TX
Member, 2006-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A, Sherwin N, Cho KH, Kim SK, Videtic G, Neumann DR, Komaki R, Macapinlac H, Bradley JD, Alavi A. Prediction of Survival by [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Locally Advanced Non-Small-Cell Lung Cancer Undergoing Definitive Chemoradiation Therapy: Results of the ACRIN 6668/RTOG 0235 Trial. J Clin Oncol 31(30):3823-30, 10/2013. PMCID: PMC3795891.
2. Frumovitz M, Querleu D, Gil-Moreno A, Morice P, Jhingran A, Munsell MF, Macapinlac HA, Leblanc E, Martinez A, Ramirez PT. Lymphadenectomy in Locally Advanced Cervical Cancer Study (LiLACS): A phase III clinical trial comparing surgical to radiologic staging in patients with stages IB2-IVA cervical cancer. J Minim Invasive Gynecol. e-Pub 7/2013. PMCID: PMC3457750.
3. Tateishi U, Terauchi T, Akashi-Tanaka S, Kinoshita T, Kano D, Daisaki H, Murano T, Tsuda H, Macapinlac HA. A comparative study on the value of dual tracer PET/CT to evaluate breast cancer. (18) F-FDG PET/CT images reveal a focal hypermetabolic focus of the primary tumor (upper panel), whereas (11) C-choline PET/CT images reveal only a focal hypermetabolic focus in the primary tumor (lower panel). Cancer Sci 103(9):Septembercover, 9/2012. PMID: 22938535.
4. Frumovitz M, Ramirez PT, Macapinlac HA, Klopp AH, Nick AM, Ramondetta LM, Jhingran A. Anatomic Location of PET-Positive Aortocaval Nodes in Patients with Locally Advanced Cervical Cancer: Implications for Surgical Staging. Int J Gynecol Cancer. e-Pub 7/2012. PMID: 22810967.
5. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. e-Pub 7/2012. PMID: 22831985.
6. Erasmus JJ, Macapinlac HA. Low-sensitivity FDG-PET studies: less common lung neoplasms. Semin Nucl Med 42(4):255-60, 7/2012. PMID: 22681674.
7. Tateishi U, Terauchi T, Akashi-Tanaka S, Kinoshita T, Kano D, Daisaki H, Murano T, Tsuda H, Macapinlac HA. A Comparative Study on the Value of Dual Tracer PET/CT to Evaluate Breast Cancer. Cancer Sci. e-Pub 5/2012. PMID: 22632272.
8. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. e-Pub 5/2012. PMID: 22586182.
9. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 5/2012. e-Pub 2/2012. PMCID: PMC3359733.
10. Tateishi U, Miyake M, Nagaoka T, Terauchi T, Kubota K, Kinoshita T, Daisaki H, Macapinlac HA. Neoadjuvant Chemotherapy in Breast Cancer: Prediction of Pathologic Response with PET/CT and Dynamic Contrast-enhanced MR Imaging--Prospective Assessment. Radiology 263(1):53-63, 4/2012. PMID: 22438441.
11. Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 117(21):4823-33, 11/2011. e-Pub 3/2011. PMCID: PMC3144261.
12. Jackson J, Pan T, Tonkopi E, Swanston N, Macapinlac HA, Rohren EM. Implementation of Automated Tube Current Modulation in PET/CT: Prospective Selection of a Noise Index and Retrospective Patient Analysis to Ensure Image Quality. J Nucl Med Technol 39(2):83-90, 6/2011. e-Pub 5/2011. PMID: 21565950.
13. Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer1: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer 117(9):1928-34, 5/2011. e-Pub 11/2010. PMID: 21509770.
14. Leibold T, Akhurst TJ, Chessin DB, Yeung HW, Macapinlac H, Shia J, Minsky BD, Saltz LB, Riedel E, Mazumdar M, Paty PB, Weiser MR, Wong WD, Larson SM, Guillem JG. Evaluation of (18)F-FDG-PET for Early Detection of Suboptimal Response of Rectal Cancer to Preoperative Chemoradiotherapy: A Prospective Analysis. Ann Surg Oncol. e-Pub 4/2011. PMID: 21476107.
15. Dickinson RL, Erwin WD, Stevens DM, Bidaut LM, Mar MV, Macapinlac HA, Wendt RE. Hybrid Modality Fusion of Planar Scintigrams and CT Topograms to Localize Sentinel Lymph Nodes in Breast Lymphoscintigraphy: Technical Description and Phantom Studies. Int J Mol Imaging 2011:298102, 2011. e-Pub 12/2010. PMCID: PMC3065894.
16. Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer1: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer. e-Pub 11/2010. PMID: 21082702.
17. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL. Prospective Imaging Assessment of Mortality Risk After Head-and-Neck Radiotherapy. Int J Radiat Oncol Biol Phys 78(3):667-74, 11/2010. e-Pub 2/2010. PMCID: PMC3072063.
18. Patnana SV, Murthy SB, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer 116(19):4487-94, 10/2010. PMID: 20629031.
19. Kr÷ger N, Bacher U, Bader P, B÷ttcher S, Borowitz MJ, Dreger P, Khouri I, Macapinlac H, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant 16(9):1187-211, 9/2010. e-Pub 6/2010. PMID: 20558311.
20. Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg 90(3):884-90; discussion 890-1, 9/2010. PMID: 20732513.
21. De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med 51(8):1213-8, 8/2010. e-Pub 7/2010. PMID: 20660382.
22. Bhosale P, Peungjesada S, Wei W, Levenback CF, Schmeler K, Rohren E, Macapinlac HA, Iyer RB. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer 20(6):936-44, 8/2010. PMID: 20683399.
23. Murthy SB, Patnana SV, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. The Standardized Uptake Value of 18-Fluorodeoxyglucose Positron Emission Tomography after Chemoradiation and Clinical Outcome in Patients with Localized Gastroesophageal Carcinoma. Oncology 78(5-6). e-Pub 8/2010. PMID: 20699623.
24. Kei PL, Vikram R, Yeung HW, Stroehlein JR, Macapinlac HA. Incidental finding of focal FDG uptake in the bowel during PET/CT: CT features and correlation with histopathologic results. AJR Am J Roentgenol 194(5):W401-6, 5/2010. PMID: 20410385.
25. N˙˝ez R, Erwin WD, Wendt RE, Stachowiak A, Mar M, Stevens D, Madewell JE, Yeung HW, Macapinlac HA. Acquisition Parameters for Oncologic Imaging with a New SPECT/Multislice CT Scanner. Mol Imaging Biol 12(2):110-38, 4/2010. PMID: 20049543.
26. De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol 21(1):33-9, 1/2010. PMID: 19602564.
27. Tonkopi E, Chi PC, Mawlawi O, Riegel AC, Rohren EM, Macapinlac HA, Pan T. Average CT in PET studies of colorectal cancer patients with metastasis in the liver and esophageal cancer patients. J Appl Clin Med Phys 11(1):3073, 2010. PMID: 20160693.
28. Macapinlac HA, Czernin J, Larson SM. Practice Based Evidence of the Beneficial Impact of PET in Patients with Brain Tumors. Mol Imaging Biol 13(1):1-2, 2010. PMID: 21082268.
29. Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac H, Wang X, Ajani JA. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer 115(22):5184-92, 11/2009. PMID: 19685531.
30. Schechter NR, Erwin WD, Yang DJ, Kim EE, Munden RF, Forster K, Taing LC, Cox JD, Macapinlac HA, Podoloff DA. Radiation dosimetry and biodistribution of (99m)Tc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 36(10):1583-91, 10/2009. PMCID: PMC2758190.
31. Podoloff DA, Ball DW, Ben-Josef E, Benson AB, Cohen SJ, Coleman RE, Delbeke D, Ho M, Ilson DH, Kalemkerian GP, Lee RJ, Loeffler JS, Macapinlac HA, Morgan RJ, Siegel BA, Singhal S, Tyler DS, Wong RJ. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw 7 Suppl 2:S1-26, 6/2009. PMID: 19555588.
32. Chuang HH, Macapinlac HA. The evolving role of PET-CT in the management of esophageal cancer. Q J Nucl Med Mol Imaging 53(2):201-9, 6/2009. PMID: 19293768.
33. De Giorgi U, Valero V, Rohren E; Shaheenah D, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche Jr HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating Tumor Cells and [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer. J Clin Oncol 27(20):3303-11, 5/2009. PMID: 19451443.
34. Macapinlac H, Segall G. Continuously Improving PET Utilization. J Nucl Med 50(5):22N-5N, 5/2009. PMID: 19403875.
35. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL. Prospective Risk-Adjusted [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography Assessment of Radiation Response in Head and Neck Cancer. J Clin Oncol 27(15):2509-15, 5/2009. PMID: 19332725.
36. Costelloe CM, Macapinlac HA, Madewell JE, Fitzgerald NE, Mawlawi OR, Rohren EM, Raymond AK, Lewis VO, Anderson PM, Bassett RL, Harrell RK, Marom EM. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med 50(3):340-7, 3/2009. PMID: 19258257.
37. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Inoue T, Macapinlac HA. Chronic thyroiditis in patients with advanced breast carcinoma: metabolic and morphologic changes on PET-CT. Eur J Nucl Med Mol Imaging 36(6):894-902, 1/2009. PMID: 19156410.
38. Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez Angulo AM, Dawood S, Resetkova E, Le-Petross HT, Yang WT. Retrospective Study of 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data. J Nucl Med 50(2):231-8, 1/2009. PMID: 19164229.
39. Vikram R, Yeung HD, Macapinlac HA, Iyer RB. Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer. AJR Am J Roentgenol 191(5):1545-51, 11/2008. PMID: 18941099.
40. Macapinlac H, Segall G. Building a Foundation for Better PET Utilization. J Nucl Med 49(9):46N-56N, 9/2008. PMID: 18765584.
41. Chi PC, Mawlawi O, Luo D, Liao Z, Macapinlac HA, Pan T. Effects of respiration-averaged computed tomography on positron emission tomography/computed tomography quantification and its potential impact on gross tumor volume delineation. Int J Radiat Oncol Biol Phys 71(3):890-9, 7/2008. PMID: 18514781.
42. Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IF. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 142(5):786-92, 6/2008. e-Pub 6/2008. PMID: 18564354.
43. Reed VK, Cavalcanti JL, Strom EA, Perkins GH, Oh JL, Tereffe W, Yu TK, Yeung H, Whitman GJ, Bedrosian I, Macapinlac HA, Buchholz TA, Woodward WA. Risk of Subclinical Micrometastatic Disease in the Supraclavicular Nodal Bed According to the Anatomic Distribution in Patients with Advanced Breast Cancer. Int J Radiat Oncol Biol Phys 71(2):435-40, 6/2008. e-Pub 12/2007. PMCID: PMC3385870.
44. Schwartz DL, Macapinlac HA, Weber RS. FDG-PET staging of head and neck cancer--can improved imaging lead to improved treatment? J Natl Cancer Inst 100(10):688-9, 5/2008. e-Pub 5/2008. PMID: 18477798.
45. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 247(1):189-96, 4/2008. PMID: 18372468.
46. Anderlini P, Swanston N, Rashid A, Bueso-Ramos C, Macapinlac HA, Champlin RE. Evidence of a graft-versus-Hodgkin lymphoma effect in the setting of extensive bone marrow involvement. Biol Blood Marrow Transplant 14(4):478-80, 4/2008. PMID: 18342791.
47. Macapinlac HA. Clinical applications of positron emission tomography/computed tomography treatment planning. Semin Nucl Med 38(2):137-40, 3/2008. PMID: 18243849.
48. Kazama T, Faria SC, Uchida Y, Ito H, Macapinlac HA. Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma. Ann Nucl Med 22(2):111-4, 3/2008. PMID: 18311535.
49. Chamilos G, Macapinlac HA, Kontoyiannis DP. The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. Med Mycol 46(1):23-9, 2/2008. PMID: 18297544.
50. Yang WT, Le-Petross HT, Macapinlac HA, Carkaci S, Gonzalez-Angulo AM, Dawood S, Resetkova E, Hortobagyi GN, Cristofanilli M. Inflammatory breast cancer: PET/CT, MRI, mammography and sonography findings. Breast Cancer Res Treat 109(3):417-26, 1/2008. PMID: 17653852.
51. Yang WT, Lane DL, Le-Petross HT, Abruzzo LV, Macapinlac HA. Breast lymphoma: imaging findings of 32 tumors in 27 patients. Radiology 245(3):692-702, 12/2007. e-Pub 10/2007. PMID: 17911538.
52. Klopp AH, Chang JY, Tucker SL, Sulman EP, Balter PA, Liu HH, Bucci MK, Macapinlac HA, Komaki R, Cox JD. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys 69(5):1409-16, 12/2007. e-Pub 9/2007. PMID: 17904303.
53. Cavalcanti JL, N˙˝ez RF, Yeung HW, Mehran RJ, Macapinlac HA. Incidental finding of prostate cancer and adenomatous colon polyp in a patient with lung cancer. Clin Nucl Med 32(11):871-3, 11/2007. PMID: 18075426.
54. Bruzzi JF, Munden RF, Truong MT, Marom EM, Sabloff BS, Gladish GW, Iyer RB, Pan TS, Macapinlac HA, Erasmus JJ. PET/CT of esophageal cancer: its role in clinical management. Radiographics 27(6):1635-52, Nov-Dec, 11/2007. PMID: 18025508.
55. Erasmus JJ, Macapinlac HA, Swisher SG. Positron emission tomography imaging in nonsmall-cell lung cancer. Cancer 110(10):2155-68, 11/2007. PMID: 17896784.
56. Namwongprom S, N˙˝ez RF, Yeung HW, Kim EE, Macapinlac HA. Unusual adrenal metastasis and abdominal carcinomatosis secondary to Hurthle cell carcinoma of the thyroid. Exp Clin Endocrinol Diabetes 115(10):694-6, 11/2007. PMID: 18058606.
57. N˙˝ez R, Yeung HW, Swanston NM, Macapinlac HA. FDG uptake in gall bladder in the PET and PET/CT scan of three oncology patients. Rev Esp Med Nucl 26(4):234-6, Jul-Aug, 7/2007. PMID: 17662192.
58. Podoloff DA, Macapinlac HA. PET and PET/CT in Management of the Lymphomas. Radiol Clin North Am 45(4):689-96, vii, 7/2007. PMID: 17706533.
59. Mar MV, Miller SA, Kim EE, Macapinlac HA. Evaluation and localization of lymphatic drainage and sentinel lymph nodes in patients with head and neck melanomas by hybrid SPECT/CT lymphoscintigraphic imaging. J Nucl Med Technol 35(1):10-6; quiz 17-20, 3/2007. PMID: 17337652.
60. Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, Correa AM, Mawlawi O, Ajani JA, Komaki RR, Fukami N, Erasmus JJ. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 109(1):125-34, 1/2007. PMID: 17146785.
61. Bruzzi JF, Truong MT, Macapinlac H, Munden RF, Erasmus JJ. Integrated CT-PET imaging of esophageal cancer: unexpected and unusual distribution of distant organ metastases. Curr Probl Diagn Radiol 36(1):21-9, Jan-Feb, 1/2007. PMID: 17198889.
62. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 1;25(13):1753-9, 2007. PMID: 17470865.
63. Won KS, Gayed I, Kim EE, Macapinlac HA. Juvenile fibroadenoma of the breast demonstrated on (111)In-octreotide SPECT and (18)F-FDG PET/CT. Eur J Nucl Med Mol Imaging 34(3):440, 2007. e-Pub 11/2006. PMID: 17119960.
64. Iyer RB, Balachandran A, Bruzzi JF, Johnson V, Macapinlac HA, Munden RF. PET/CT and hepatic radiation injury in esophageal cancer patients. Cancer Imaging 7:189-94, 2007. PMID: 18055293.
65. Namwongprom S, N˙˝ez R, Kim EE, Macapinlac HA. Tc-99m MDP bone scintigraphy and positron emission tomography/computed tomography (PET/CT) imaging in Erdheim-Chester disease. Clin Nucl Med 32(1):35-8, 2007. PMID: 17179801.
66. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C. We should desist using RECIST, at least in GIST. J Clin Oncol 25(13):1760-4, 2007. PMID: 17470866.
67. Bruzzi JF, Truong MT, Marom EM, Mawlawi O, Podoloff DA, Macapinlac HA, Munden RF. Incidental findings on integrated PET/CT that do not accumulate 18F-FDG. AJR Am J Roentgenol 187(4):1116-23, 10/2006. PMID: 16985164.
68. Munden RF, Truong MT, Gladish GW, Podoloff DA, Mawlawi O, Broemeling LD, Bruzzi JF, Macapinlac HA. Interobserver and intraobserver variability of standardized uptake value measurements in non-small-cell lung cancer. J Thorac Imaging 21(3):205-12, 8/2006. PMID: 16915065.
69. Erasmus JJ, Munden RF, Truong MT, Ho JJ, Hofstetter WL, Macapinlac HA, Correa AM, Wu TT, Bruzzi JF, Marom EM, Sabloff BS, Ajani JA, Komaki R, Liao Z, Lee JH, Fukami N, Bresalier R, Swisher SG. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol 1(5):478-86, 6/2006. PMID: 17409902.
70. Santiago JF, Gonen M, Yeung H, Macapinlac H, Larson S. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging 50(1):61-7, 3/2006. PMID: 16557205.
71. Pawlik TM, Erasmus JJ, Truong MT, Macapinlac HA, Ross MI, Gershenwald JE. Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma. Am J Roentgenol 187(1):W117-9, 2006. PMID: 16794124.
72. Pan T, Mawlawi O, Luo D, Liu HH, Chi PC, Mar MV, Gladish G, Truong M, Erasmus J, Jr, Liao Z, Macapinlac HA. Attenuation correction of PET cardiac data with low-dose average CT in PET/CT. Med Phys 33(10):3931-8, 2006. PMID: 17089855.
73. Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, Munden RF. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 47(8):1267-73, 2006. PMID: 16883004.
74. Trent JC, Ramdas L, Dupart J, Hunt K, Macapinlac H, Taylor E, Hu L, Salvado A, Abbruzzese JL, Pollock R, Benjamin RS, Zhang W. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. Cancer 107(8):1898-908, 2006. PMID: 16986125.
75. Munden RF, Macapinlac HA, Erasmus JJ. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy. J Thorac Imaging 21(2):137-45, 2006. PMID: 16770230.
76. Mawlawi O, Pan T, Macapinlac HA. PET/CT imaging techniques, considerations, and artifacts. J Thorac Imaging 21(2):99-110, 2006. PMID: 16770227.
77. Macapinlac HA. Positron emission tomography of the brain. Neuroimaging Clin N Am 16(4):591-603, 2006. PMID: 17148021.
78. Mawlawi O, Erasmus JJ, Munden RF, Pan T, Knight AE, Macapinlac HA, Podoloff DA, Chasen M. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. AJR Am J Roentgenol 186(2):308-19, 2006. PMID: 16423932.
79. Mawlawi O, Erasmus JJ, Pan T, Cody DD, Campbell R, Lonn AH, Kohlmyer S, Macapinlac HA, Podoloff DA. Truncation artifact on PET/CT: impact on measurements of activity concentration and assessment of a correction algorithm. AJR Am J Roentgenol 186:1458-67, 2006. PMID: 16632745.
80. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23(6):1136-43, 2005. PMID: 15718309.
81. Pan T, Mawlawi O, Nehmeh SA, Erdi YE, Luo D, Liu HH, Castillo R, Mohan R, Liao Z, Macapinlac H. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med 46(9):1481-7, 2005. PMID: 16157531.
82. Martinez-Roman S, Ramirez PT, Oh J, Viciedo MG, Macapinlac H. Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma. Gynecol Oncol 96(3):888-91, 2005. PMID: 15721446.
83. Kazama T, Swanston N, Podoloff DA, Macapinlac HA. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging 32(12):1406-11, 2005. PMID: 16133379.
84. Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 25(1):191-207, 2005. PMID: 15653595.
85. Macapinlac HA. FDG-PET in head and neck, and thyroid cancer. Chang Gung Med J 28(5):284-95, 2005. PMID: 16086543.
86. Macapinlac HA. FDG-PET in the evaluation of cervical cancer. Gynecol Oncol 99(3 Suppl 1):S171-2, 2005. PMID: 16419203.
87. Yi JG, Marom EM, Munden RF, Truong MT, Macapinlac HA, Gladish GW, Sabloff BS, Podoloff DA. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer. Radiology 236(1):271-5, 2005. PMID: 15987980.
88. Chen LL, Sabripour M, Andtbacka RH, Patel SR, Feig BW, Macapinlac HA, Choi H, Wu EF, Frazier ML, Benjamin RS. Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep 7(4):293-9, 2005. PMID: 15946589.
89. Erasmus JJ, Truong MT, Smythe WR, Munden RF, Marom EM, Rice DC, Vaporciyan AA, Walsh GL, Sabloff BS, Broemeling LD, Stevens CW, Pisters KM, Podoloff DA, Macapinlac HA. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg 129(6):1364-70, 2005. PMID: 15942579.
90. Truong MT, Erasmus JJ, Macapinlac HA, Marom EM, Mawlawi O, Gladish GW, Sabloff BS, Bruzzi JF, Munden RF. Integrated positron emission tomography/computed tomography in patients with non-small cell lung cancer: normal variants and pitfalls. J Comput Assist Tomogr 29(2):205-209, 2005. PMID: 15772538.
91. Phongkitkarun S, Varavithya V, Kazama T, Faria SC, Mar MV, Podoloff DA, Macapinlac HA. Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose. World J Gastroenterol 11(46):7284-9, 2005. PMID: 16437629.
92. Frank SJ, Chao KS, Schwartz DL, Weber RS, Apisarnthanarax S, Macapinlac HA. Technology insight: PET and PET/CT in head and neck tumor staging and radiation therapy planning. Nat Clin Pract Oncol 2(10):526-33, 2005. PMID: 16205772.
93. Macapinlac HA. FDG PET and PET/CT imaging in lymphoma and melanoma. Cancer J 10:262-70, 7/2004. PMID: 15383207.
94. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Jr, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101(18):1776-85, 2004. PMID: 15386332.
95. Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64(17):5913-9, 2004. PMID: 15342366.
96. Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, Macapinlac HA, Podoloff DA. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 183(6):1619-28, 2004. PMID: 15547201.
97. Truong MT, Erasmus JJ, Munden RF, Marom EM, Sabloff BS, Gladish GW, Podoloff DA, Macapinlac HA. Focal FDG uptake in mediastinal brown fat mimicking malignancy: a potential pitfall resolved on PET/CT. AJR Am J Roentgenol 183(4):1127-32, 2004. PMID: 15385319.
98. Mawlawi O, Podoloff DA, Kohlmyer S, Williams JJ, Stearns CW, Culp RF, Macapinlac H. Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes. J Nucl Med 45(10):1734-42, 2004. PMID: 15471842.
99. Truong MT, Erasmus JJ, Macapinlac HA, Podoloff DA. Teflon injection for vocal cord paralysis: false-positive finding on FDG PET-CT in a patient with non-small cell lung cancer. AJR Am J Roentgenol 182(6):1587-9, 2004. PMID: 15150014.
100. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45(1):17-21, 2004. PMID: 14734662.
101. Macapinlac HA. The utility of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma. Mol Imaging Biol 6(4):200-7, 2004. PMID: 15262235.
102. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78(4):1152-60; discussion 1152-60, 2004. PMID: 15464463.
103. Gayed I, Vu T, Johnson M, Macapinlac H, Podoloff D. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol 5(1):26-31, 2003. PMID: 14499159.
104. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med 44(9):1407-1412, 2003. PMID: 12960184.
105. Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, Heelan RT, Macapinlac HA, Jung SH, Silvestri GA, Siegel BA, Rusch VW. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 126(6):1943-1951, 2003. PMID: 14688710.
106. Nunez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI, Larson SM. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43(1):46-55, 2002. PMID: 11801702.
107. Nehmeh SA, Erdi YE, Ling CC, Rosenzweig KE, Schoder H, Larson SM, Macapinlac HA, Squire OD, Humm JL. Effect of respiratory gating on quantifying PET images of lung cancer. J Nucl Med 43(7):876-881, 2002. PMID: 12097456.
108. Sanchez Salmon A, Nunez R, Yeung H, Healey J, Macapinlac HA. FGD PET in a patient with pseudofractures from osteomalacia. Rev Esp Med Nucl 21(1):34-35, 2002. PMID: 11821000.
109. Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac HA, Siedlecki K, Verbel D, Schwartz L, Larson SM, Scher HI. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59(6):913-918, 2002. PMID: 12031380.
110. Etchebehere EC, Macapinlac HA, Gonen M, Humm K, Yeung HW, Akhurst T, Scher HI, Larson SM. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET. Q J Nucl Med 46(2):122-130, 2002. PMID: 12114875.
111. Erdi YE, Rosenzweig K, Erdi AK, Macapinlac HA, Hu YC, Braban LE, Humm JL, Squire OD, Chui CS, Larson SM, Yorke ED. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 62:51-60, 2002. PMID: 11830312.
112. Yeung HW, Sanches A, Squire OD, Macapinlac HA, Larson SM, Erdi YE. Standardized uptake value in pediatric patients: an investigation to determine the optimum measurement parameter. Eur J Nucl Med Mol Imaging 29:61-66, 2002. PMID: 11807608.
113. Turlakow A, Yeung HW, Pui J, Macapinlac HA, Liebovitz E, Rusch V, Goy A, Larson SM. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med 161(7):1003-7, 4/2001. PMID: 11295964.
114. Ramos CD, Chisin R, Yeung HW, Larson SM, Macapinlac HA. Incidental focal thyroid uptake on FDG positron emission tomographic scans may represent a second primary tumor. Clin Nucl Med 26(3):193-197, 3/2001. PMID: 11245108.
115. Macapinlac HA. Clinical usefulness of FDG PET in differentiated thyroid cancer. J Nucl Med 42(1):77-8, 2001. PMID: 11197984.
116. Ramos CD, Erdi YE, Gonen M, Riedel E, Yeung HW, Macapinlac HA, Chisin R, Larson SM. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med 28:155-164, 2001. PMID: 11303885.
117. Turlakow A, Larson SM, Coakley F, Akhurst T, Gonen M, Macapinlac HA, Kelly W, Leibel S, Humm J, Scardino P, Scher H, Hricak H. Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose: comparison of filtered back projection and iterative reconstruction with segmented attenuation correction. Q J Nucl Med 45(3):235-424, 2001. PMID: 11788816.
118. Chisin R, Macapinlac HA. The indications of FDG-PET in neck oncology. Radiol Clin North Am 38(5):999-1012, 9/2000. PMID: 11054965.
119. Imbriaco M, Akhurst T, Hilton S, Yeung HW, Macapinlac HA, Mazumdar M, Pace L, Kemeny N, Erdi Y, Cohen A, Fong Y, Guillem J, Larson SM. Whole-Body FDG-PET in Patients with Recurrent Colorectal Carcinoma. A Comparative Study with CT. Clin Positron Imaging 3(3):107-114, 5/2000. PMID: 11008100.
120. McCaffrey JA, Reuter VV, Herr HW, Macapinlac HA, Russo P, Motzer RJ. Carcinoid tumor of the kidney. The use of somatostatin receptor scintigraphy in diagnosis and management. Urol Oncol 5(3):108-111, 4/2000. PMID: 10765017.
121. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H, Rosai J, Robbins RJ. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85(3):1107-13, 3/2000. PMID: 10720047.
122. Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM. Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature. Endocr Pract 6(6):460-464, 2000. PMID: 11155220.
123. Nunez RF, Yeung HW, Macapinlac HA, Castro-Malaspina H, Larson SM. Ga-67 uptake in cutaneous lesions of graft-versus-host disease. Clin Nucl Med 25(9):676-678, 2000. PMID: 10983752.
124. Robbins RJ, Hill RH, Wang W, Macapinlac HA, Larson SM. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 10(2):177-183, 2000. PMID: 10718556.
125. Guillem JG, Puig-La Calle J, Jr, Akhurst T, Tickoo S, Ruo L, Minsky BD, Gollub MJ, Klimstra DS, Mazumdar M, Paty PB, Macapinlac HA, Yeung H, Saltz L, Finn RD, Erdi Y, Humm J, Cohen AM, Larson S. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 43(1):18-24, 2000. PMID: 10813118.
126. Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, Reich L, Flombaum C, Mariani T, Tong WP, Bosl GJ. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18(6):1173-1180, 2000. PMID: 10715285.
127. Erdi YE, Macapinlac HA, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, Yorke ED. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 27(7):861-866, 2000. PMID: 10952499.
128. Macapinlac HA, Yeung HW, Larson SM. Defining the Role of FDG PET in Head and Neck Cancer. Clin Positron Imaging 2(6):311-316, 11/1999. PMID: 14516613.
129. Rini JN, Yeung HW, Nunez RF, la Calle JP, Larson S, Macapinlac HA. FDG-PET Patterns of Abdominal Carcinomatosis. Clin Positron Imaging 2(6):333, 11/1999. PMID: 14516630.
130. Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291-302, 7/1999. PMID: 10404792.
131. Macapinlac HA, Humm JL, Akhurst T, Osman I, Pentlow K, Shangde C, Yeung HW, Squire O, Finn RD, Scher HI, Larson SM. Differential Metabolism and Pharmacokinetics of L-[1-(11)C]-Methionine and 2-[(18)F] Fluoro-2-deoxy-D-glucose (FDG) in Androgen Independent Prostate Cancer. Clin Positron Imaging 2(3):173-181, 1999. PMID: 14516541.
132. Yeung HW, Macapinlac HA, Mazumdar M, Bains M, Finn RD, Larson SM. FDG-PET in Esophageal Cancer. Incremental Value over Computed Tomography. Clin Positron Imaging 2:255-260, 1999. PMID: 14516649.
133. Nunez RF, Yeung HW, Macapinlac H. Increased F-18 FDG uptake in the stomach. Clin Nucl Med 24:281-282, 1999. PMID: 10466532.
134. Erdi YE, Macapinlac HA, Larson SM, Erdi AK, Yeung H, Furhang EE, Humm JL. Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 PET Imaging. Clin Positron Imaging 2(1):41-46, 1999. PMID: 14516552.
135. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung HW, Humm JL, Guillem J, Downey R, Karpeh M, Cohen AE, Ginsberg R. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging 2(3):159-171, 1999. PMID: 14516540.
136. Fong Y, Saldinger PF, Akhurst T, Macapinlac HA, Yeung H, Finn RD, Cohen A, Kemeny N, Blumgart LH, Larson SM. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 178(4):282-287, 1999. PMID: 10587184.
137. Adler ML, Macapinlac HA, Robbins RJ. Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin. Endocr Pract 4(5):282-286, 9/1998. PMID: 15251726.
138. Yeung HW, Macapinlac H, Karpeh M, Finn RD, Larson SM. Accuracy of FDG-PET in Gastric Cancer. Preliminary Experience. Clin Positron Imaging 1(4):213-221, 1998. PMID: 14516555.
139. Akhurst T, Boland P, Macapinlac H, Finn R, Yeung HW, Squire O, Larson SM. Excess Muscle FDG Uptake in an Euglycaemic Patient That Is Corrected by Fasting. Clin Positron Imaging 1(2):131-133, 1998. PMID: 14516602.
140. Macapinlac HA, Larson SM. Positron emission tomography (PET)--measured biochemical response to radiotherapy of laryngeal tumors. Cancer J Sci Am 3(6):333-335, 1997. PMID: 9403044.
141. el-Shirbiny AM, Yeung H, Imbriaco M, Michaeli J, Macapinlac H, Larson SM. Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. J Nucl Med 38(8):1208-1210, 1997. PMID: 9255151.
142. Yeung H, Macapinlac H. First impressions. A 21-yr-old woman with adenocarcinoma of the pelvis. What is the radiopharmaceutical? What are the findings? J Nucl Med 37(12):7A, 1994, 12/1996. PMID: 8999117.
143. Yeung HW, Imbriaco M, Zhang JJ, Macapinlac H, Goldsmith SJ, Larson SM. Visualization of myocardial metastasis of carcinoid tumor by indium-111-pentetreotide. J Nucl Med 37(9):1528-30, 9/1996. PMID: 8790210.
144. Daghighian F, Humm JL, Macapinlac HA, Zhang J, Izzo J, Finn R, Kemeny N, Larson SM. Pharmacokinetics and dosimetry of iodine-125-IUdR in the treatment of colorectal cancer metastatic to liver. J Nucl Med 37(4 Suppl):29S-32S, 4/1996. PMID: 8676201.
145. Macapinlac H, Kemeny N, Daghighian F, Finn R, Zhang J, Humm J, Squire O, Larson SM. Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. J Nucl Med 37(4 Suppl):25S-29S, 4/1996. PMID: 8676200.
146. Abdel-Dayem H, Bag R, Macapinlac H, Elgazzar AH, Habbab N, Pescatore F, Kempf J. Diffuse Tl-201 uptake in the lungs. Etiologic classification and pattern recognition. Clin Nucl Med 20(2):164-72, 2/1995. PMID: 7720309.
147. Caluser C, Scott A, Macapinlac H, Yeh S, Rosenfelt N, Farid B, Abdel-Dayem HM, Larson SM, Kalaigian H. Extramedullary hematopoiesis assessment in a patient with osteopetrosis. Clin Nucl Med 20(1):75, 1995. PMID: 7895447.
148. Scott AM, Macapinlac HA, Zhang J, Daghighian F, Montemayor N, Kalaigian H, Sgouros G, Graham MC, Kolbert K, Yeh SD. Image registration of SPECT and CT images using an external fiduciary band and three-dimensional surface fitting in metastatic thyroid cancer. J Nucl Med 36:100-103, 1995. PMID: 7799059.
149. Goldsmith SJ, Macapinlac HA, O'Brien JP. Somatostatin receptor imaging in lymphoma. Semin Nucl Med 25(3):262-271, 1995. PMID: 7570045.
150. Reinsel RA, Veselis RA, Feshchenko VA, Di Resta GR, Mawlawi O, Beattie B, Silbersweig D, Stern E, Blasberg R, Macapinlac H. Target detection and the prefrontal cortex. A PET scan study of the P300 event-related potential. Ann N Y Acad Sci 769:393-397, 1995. PMID: 8595041.
151. Larson, SM, Divgi, CR, Scott, AM, Daghighian, F, Macapinlac, HA, Welt, S. Current status of radioimmunodetection. Nucl Med Biol 215(5):721-729, 7/1994. PMID: 9241648.
152. Scott AM, Macapinlac H, Zhang JJ, Kalaigian H, Graham MC, Divgi CR, Sgouros G, Goldsmith SJ, Larson SM. Applications of fusion imaging in oncology. Nucl Med Biol 21(5):775-784, 1994. PMID: 9241654.
153. Scott AM, Macapinlac HA, Divgi CR, Zhang JJ, Kalaigian H, Pentlow K, Hilton S, Graham MC, Sgouros G, Pelizzari C, et al. Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma. J Nucl Med 35(12):1976-84, 1994. PMID: 7989980.
154. Schneider JA, Divgi CR, Scott AM, Macapinlac HA, Seidman AD, Goldsmith SJ, Larson SM. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med 35(11):1748-1752, 1994. PMID: 7525900.
155. Macapinlac HA, Scott AM, Larson SM, Divgi CR, Yeh SD, Goldsmith SJ. Gallium-67-citrate imaging in nuclear oncology. Nucl Med Biol 21(5):731-738, 1994. PMID: 9241649.
156. Tjuvajev JG, Macapinlac HA, Daghighian F, Scott AM, Ginos JZ, Finn RD, Kothari P, Desai R, Zhang J, Beattie B, et al. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J Nucl Med 35(14):1407-1418, 1994. PMID: 8071684.
157. Caluser CI, Abdel-Dayem HM, Macapinlac HA, Scott A, Healey JH, Huvos A, Kalaigian H, Yeh SD, Larson SM. The value of thallium and three-phase bone scans in the evaluation of bone and soft tissue sarcomas. Eur J Nucl Med 21:1198-1205, 1994. PMID: 7859771.
158. Abdel-Dayem HM, Scott A, Macapinlac H, Larson S. Tracer imaging in lung cancer. Eur J Nucl Med 21(1):57-81, 1994. PMID: 8088287.
159. Rusch V, Macapinlac H, Heelan R, Kramer E, Larson S, McCormack P, Burt M, Martini N, Ginsberg R. NR-LU-10 monoclonal antibody scanning. A helpful new adjunct to computed tomography in evaluating non-small-cell lung cancer. J Thorac Cardiovasc Surg 106(2):200-4, 8/1993. PMID: 8393504.
160. Daghighian F, Pentlow KS, Larson SM, Graham MC, DiResta GR, Yeh SD, Macapinlac H, Finn RD, Arbit E, Cheung NK. Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma. Eur J Nucl Med 20(5):402-9, 5/1993. PMID: 8519259.
161. Schneider JA, Divgi CR, Scott AM, Macapinlac HA, Sonenberg M, Goldsmith SJ, Larson SM. Hiatal hernia on whole-body radioiodine survey mimicking metastatic thyroid cancer. Clin Nucl Med 18(9):751-753, 1993. PMID: 8403716.
162. Larson SM, Macapinlac HA, Scott AM, Divgi CR. Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors. Acta Oncol 32(7/8):709-715, 1993. PMID: 8305216.
163. Roistacher N, Preminger M, Macapinlac H, Pierri MK. Myocardial entrapment by lymphoma: a cause of reversible segmental left ventricular dysfunction. Am Heart J 124(2):516-521, 8/1992. PMID: 1636600.
164. Caluser C, Healey J, Macapinlac H, Kostakoglu L, Abdel-Dayem HM, Larson SM, Yeh SD. Thallium uptake in recurrent pigmented villonodular synovitis. Correlation with three-phase bone scanning. Clin Nucl Med 17(9):751-3, 1992. PMID: 1395357.
165. Caluser C, Macapinlac H, Healey J, Ghavimi F, Meyers P, Wollner N, Kalaigian J, Kostakoglu L, Abdel-Dayem HM, Yeh SD, et al. The relationship between thallium uptake, blood flow, and blood pool activity in bone and soft tissue tumors. Clin Nucl Med 17(7):565-72, 1992. PMID: 1638838.
166. Hoener B, Engelstad BL, Ramos EC, Macapinlac HA, Price DC, Johnson TR, White DL. Comparison of Fe-HBED and Fe-EHPG as hepatobiliary MR contrast agents. J Magn Reson Imaging 1:357-62, 5/1991. PMID: 1802149.

Invited Articles

1. Macapinlac HA, Larson SM. Positron Emission Tomography (PET)-measured biochemical response to radiotherapy of laryngeal tumors. Cancer J Sci Am 3(6):333-5, 1997.
2. Abdel-Dayem HM, Scott A, Macapinlac H, Larson S. Tracer imaging in lung cancer. Eur J Nucl Med (1):57-81, 1994.
3. Macapinlac HA, Larson SM. Whole body PET in oncology. Oncology 7(7):52-55, 1993.
Other Articles
1. Nunez R, Yeung HW, Swanston NM, Macapinlac HA. FDG uptake in gall bladder in the PET and PET/CT scan of three oncology patients. Rev Esp Med Nucl 26(4):234-6, 11/2007.

Abstracts

1. Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 after neoadjuvant therapy and surgery for esophageal cancer: an orphan status. 46th Annual Meeting Program, The Society of Thoracic Surgeons(44):174-175, 1/2010.
2. Yoo DC, Hillman S, Macapinlac HA, Fernando H, Rilling WS, Shepard JO, et al. F-18 FDC PET/CT in Stage 1A NSCLC after RFA: Initial Report from a Cooperative Group Trial - American College of Surgeons Oncology Group Z4033. RSNA 2009 Scientific Assembly and Annual Meeting Program:688, 11/2009.
3. Pan T, Gould L, Mawlawi O, Gladish, Rohren E, Macapinlac H. Assessment of heart motion during respiration with cine CT without gating in cardiac PET. J Nucl Med 49:384P, 5/2008.
4. Jackson J, Smith A, Swanston N, Chasen B, Fitzgerald N, Rohren E, Macapinlac H. Bismuth shielding: A tool to reduce CT dose to female pediatric breast tissue during PET/CT acquisition, while not compromising image data. J Nucl Med 59:416P, 5/2008.
5. Jackson J, Smith A, Pan T, Swanston N, Rohren E, Macapinlac H. Bismuth shielding: Evaluation of benefits and effects on PET/CT acquisition. J Nucl Med 49:422P, 5/2008.
6. Chang T, Pan T, Riegel A, Chang G, Rohren E, Macapinlac H, Mawlawi O. Comparison of internal target volumes for treatment planning using CT and PET. J Nucl Med 49:325P, 5/2008.
7. Riegel A, Mawlawi O, Rohren E, Macapinlac H, Pan T. Determination of PET thresholds for solitary pulmonary tumors in radiation treatment planning. J Nucl Med 49:382P, 5/2008.
8. Chang T, Pan T, Chang G, Rohren E, Macapinlac H, Mawlawi O. Effects of scan duration and count density on the quantitative accuracy of PET images. J Nucl Med 49:395P, 5/2008.
9. Pan T, Gould L, Mawlawi O, Mar M, Rohren E, Macapinlac H. Investigation of helical CT with rigid body translation for attenuation correction of cardiac PET data. J Nucl Med 49:390P, 5/2008.
10. Nunez R, Namwongprom S, Stachowiak A, Mar M, Yeung H, Macapinlac H. Added value of SPECT/Multislice CT over diagnostic whole body planar imaging in patients with thyroid carcinoma. J Nucl Med 48:266P-a, 2007.
11. Mawlawi O, Truong M, Marom E, Pan T, Sabloff B, Bruzzi J, Erasmus J, Yeung H, Macapinlac H. Clinical evaluation of 2D versus 3D whole body FDG imaging performed on two PET scanners with different detectors. J Nucl Med 48:442P-a, 2007.
12. Tonkopi E, Mawlawi O, Chi PC, Yeung H, Macapinlac H, Pan T. Effect of Average CT on quantifying PET images of colorectal cancer metastasis in the liver. J Nucl Med 48:411P-a, 2007.
13. Chi PC, Mawlawi O, Yeung H, Macapinlac H, Pan T. Effect of average CT on quantifying PET images of lung cancer. J Nucl Med 48:96P, 2007.
14. Jackson J, Pan T, Swanston N, Macapinlac H, Podoloff D, Mawlawi O. Effects of detector malfunction on PET quantification accuracy. J Nucl Med 48:462P, 2007.
15. Mar MV, Miller SA, Kim, EE, Macapinlac HA. Evaluation and localization of lymphatic rainage and sentinel lymph nodes in patients with head and neck melanomas by hybrid SPECT/CT. J Nucl Med 35(1):10-16, 2007.
16. Dickinson R, Mar M, Erwin W, Bidaut L, Mawlawi O, Macapinlac H, Wendt R. Investigation of a novel approach to localizing the sentinel node in breast lymphoscintigraphy: Fusion of planar scintigrams and CT topograms. J Nucl Med 48:425P-a, 2007.
17. Mawlawi O, Yahil A, Vija H, Erwin W, Macapinlac H. Reduction in scan duration or injected dose in planar bone scintigraphy enabled by Pixon« post-processing. J Nucl Med 48:13P-b, 2007.
18. Jackson J, Pan T, Swanston N, Macapinlac H, Podoloff D. Strategy to reduce CT dose and maintain image quality for small body habitus patients in PET/CT. J Nucl Med 48:450P-b, 2007.
19. Mawlawi O, Erwin W, Pan T, Wendt III R, Chasen B, Nunez R, Yeung H, Macapinlac H. What is the optimal minimum whole body bone SPECT scan duration that can replace planar bone scintigraphy?. J Nucl Med 48:120P-c, 2007.
20. Mawlawi O, Pan T, Baghaei H, Swanston N, Darensborg B, Erasmus J, Macapinlac H. A comparison of lesion detectability among four different PET scanners. J Nucl Med 47(366P-a), 2006.
21. Pan T, Mawlawi O, Nehmeh S, Erdi Y, Chi PC, Luo D, Truong M, Erasmus J, Macapinlac H. Attenuation correction of cardiac PET data with respiration-averaged CT on PET/CT data with respiration-averaged CT on PET/CT. J Nucl Med 47(385P-a), 2006.
22. Mawlawi O, Erwin W, Pan T, Bartosh J, Kim E, Macapinlac H. Can whole body bone SPECT replace planar imaging when acquired over a similar duration?. J Nucl Med 47:62P-a, 2006.
23. Mawlawi O, Pan T, Qiao F, Devaraju V, Lofton B, Truong M, Macapinlac H. How long should gated PET/CT scans be in order to generate individual images with good quality??. J Nucl Med 47:388P-b, 2006.
24. Pan T, Mawlawi O, Nehmeh S, Erdi Y, Chi P, Luo D, Truong M, Erasmus J, Macapinlac H. New low dose cine CT for quantitation of the PET data in the thorax on PET/CT. J Nucl Med 47:395P, 2006.
25. Pan T, Hamill J, Luo D, Mawlawi O, Macapinlac H. PET imaging of the thorax with attenuation correction by time-averaging and attenuation-averaging of CT data from 4DCT. J Nucl Med 47:192P-b, 2006.
26. Pan T, Mawlawi O, Nehmeh SA, Erdi YE, Luo D, Liu HH, Castillo R, Mohan R, Liao Z, Macapinlac HA. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med 46(9):1481-1487, 2005.
27. Mawlawi O, Podoloff DA, Kohlmyer S, Williams JJ, Stearns CW, Culp RF, Macapinlac HA. Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes. J Nucl Med 45(10):1734-1742, 2004.
28. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D. The role of F18-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45(1):17-21, 1, 2004.
29. Gayed I, Vu T, Johnson M, Macapinlac HA, Podoloff DA. Comparison of bone and 2-deoxy-2-(18F) fluoroglucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol 5(1):26-31P, 2003.
30. Mawlawi O, Kohlmyer S, Podoloff DA, Macapinlac H. Evaluation of clinical image quality and lesion detectability of the discovery ST (DST) PET/CT scanner. J Nucl Med 44 (Suppl)(5):282p, 2003.
31. Varavithya V, Phongkitkarun S, Kazama T, Faria SC, Mar M, Podoloff DA, Macapinlac HA. FDG-PET in Lymphoma of the liver: Lesion detection by FDG-PET vs. CT. J Nucl Med 44(5):83P, 2003.
32. Kazama T, Swanston N, Podoloff DA, Macapinlac HA. Granulocyte colony stimulating factor: an investigation on increased uptake and optimal length of time for diagnosis when used with F-18 FDG PET. J Nucl Med 44(5):187p, 2003.
33. Forster KM, Mawlawi O, Cody D, Steadham RE, Chao C, Guerrero R, Komaki R, Kohlmyer S, Macapinlac H. Identification of acceptance criteria and testing of a PET/CT scanner for radiotherapy treatment planning. J Nucl Med 44 (Suppl)(5):291p, 2003.
34. Phongkitkarun S, Varavithya V, Kazama T, Faria SC, Mar M, Podoloff DA, Macapinlac HA. Lymphomatous involvement of the gastrointestinal tract: evaluation by positron emission tomography (PET) with 18F-Fluorodeoxyglucose (18F-FDG). J Nucl Med 44(5):83p, 2003.
35. Mawlawi O, Kohlmyer S, Williams JJ, Stearns CW, Culp RF, Podoloff DA, Macapinlac HA. Performance characteristics of the GE discovery ST PET/CT scanner using the nema standard. J Nucl Med 44(5):111p, 2003.
36. Turkakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal Carcinomatosis: Role of (18)F-FDG PET. J Nucl Med 44(9):1407-9, 2003.
37. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen-Forster K, Roth J, Putnam JB, Moran C, Cox JD. SUV by FDG-PET predicts outcome of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 57 (Suppl)(2):S166, 2003.
38. Ozaki K, Yang DJ, Macapinlac HA, Yu D, Kohanim S, Kim EE, Podoloff DA. 18F-Fluoropenciclovir for PET assessment of HSV-TK reporter gene expression and localization. J Nucl Med 42(1109):274P, 2002.
39. Gayed I, Vu T, Macapinlac HA. Comparison of Bone and F-18 FDG Scans in the Evaluation of Bony Metastases. J Nucl Med 43(Suppl):285P, 2002.
40. Yang DJ, Macapinlac HA, Yu D, Azhdarinia A, Kohanim S, Bryant JL, Kim EE, Podoloff DA. Glucosamine pathway imaging using 99mTc-EC-deoxyglucose in comparison with 18F-FDG. J Nucl Med 43(1478):368P, 2002.
41. Gayed I, Sureshbabu W, Iyer R, Macapinlac H Johnson M, Podoloff DA. Positron emission tomography versus computerized tomography for identification of melanoma metastases. J Nucl Med 43(1187):294P, 2002.
42. Macapinlac HA, Podoloff DA, Swanston N, Acoy D, Mawlawi O, Champagne J. Utility of FDG PET in identifying richters transformation in patients with chronic lymphocytic leukemia (CLL). J Nucl Med 43(108):30P, 2002.
43. Machac J, Zhang Z, Nunez R, Chen WT, Macapinlac HA, Larson SM. 18F Fluorodeoxyglucose uptake in human thoracic aortas assessed in vivo by positron emission tomography. J Nucl Med 42(201):54P, 2001.
44. Nehmeh SA, Ford E, Macapinlac HA, Larson SM, Mageras G, Yorke E, Humm J, Sidhu K, Pentlow K, Squire O, Yusef E. Gated positron emission tomography: A technique for reducing lung tumor motion effect. J Nucl Med 42(124):34P, 2001.
45. Yeung HW, Erdi Y, Squire O, Macapinlac HA, Larson SM. Standardized uptake value normalized to body surface area (SUVBSA) for pediatric patients. J Nucl Med 42(815):189P, 2001.
46. Erdi YE, Yorke ED, Erdi AK, Hu YC, Braban LE, Macapinlac H, Humm JL, Squire OD, Larson SM, Chui CS, Rosenzweig K. The role of PET in radiotherapy treatment planning for patients with non-small cell lung cancer (NSCLC). J Nucl Med 42(1255):302P, 2001.
47. Santiago JF, Macapinlac HA, Yeung H, Larson SM. The uptake of 18F-FDG PET scans in the management of 133 breast cancer patients. J Nucl Med 42(1236):297P, 2001.

Book Chapters

1. Eric M. Rohren, Homer A. Macapinlac. PET Imaging of Prostate Cancer: Other Tracers. In: PET Clinics. 4:2. Ed(s) Hossein Jadvar. SAUNDERS: New York, NY, 185-192, 2009. ISBN: 1556-8598.
2. Macapinlac HA. FDG PET in Breast Cancer. In: Advanced Therapy of Breast Disease. BC Decker, 2004.
3. Abdel-Dayem HM, Scott AM, Macapinlac, HA. Thallium 201 Chloride: A Tumor Imaging Agent. In: Nuclear Medicine in Clinical Diagnosis and Treatment. Churchill Livingston, 71-81, 2004.
4. Macapinlac HA. The Role of PET in Planning Radiation Therapy and Monitoring Itĺs Effects. In: Nuclear Medicine Annual. Lippincott, Williams, & Wilkins, 163-173, 2004.
5. Macapinlac HA. Head and Neck Cancer. In: Principles and Practice of Positron Emission Tomography. Lippincott, Williams, & Wilkins, 2002.
6. Macapinlac HA. Hepatic Artery Pump Evaluation Prior to Locoregional Chemotherapy of Hepatic Metastases from Colorectal Cancer in Nuclear Medicine. Lippincott, Williams, and Wilkins, 2000.
7. Chisin R, Macapinlac HA. The Indications of FDG PET in Head and Neck Oncology. In: Radiol Clin North Am. 38, 999-1012, 2000.
8. Abdel-Dayem, HM, Macapinlac, HA. Malignant Lymphoma. In: Clinical Nuclear Medicine. Thomson Science & Professional, 517- 524, 1998.
9. Abdel-Dayem, HM, Macapinlac, HA. Thallium 201 Chloride, A Tumor Imaging Agent. In: Nuclear Medicine in Clinical Diagnosis and Treatment. Churchill Livingston, 831-842, 1998.
10. Macapinlac HA. The Role of Nuclear Medicine in the Diagnosis and Treatment of Liver Metastases from Colorectal Carcinoma. In: Nuclear Medicine Annual. Lippincott-Raven Publishers, 163-179, 1997.
11. Finn, R, Macapinlac, HA, Humm, J, Pentlow, K, McDevitt, M, Tjuvajev, JBlasberg, R, Scheinberg, D, Larson, SM, Zweit, J. Application of PET radionuclides for nuclear medicine targeted therapies. In: Application of accelerators in research and industry: Proceedings of the 14th International Conference. American Institute of Physics, 1345-1347, 1996.
12. Finn, RD, Divgi, CR, Goldsmith, SJ, Larson, SM, Macapinlac, HA, Scott, AM, Yeh, SDJ. Radionuclides and their application to oncology research. In: Chemistsĺ views of imaging centers. Plenum Press, 277-284, 1995.
13. Abdel-Dayem, HM, Macapinlac, HA, Larson, SM, Scott, AM. Adult malignancy: thallium scintigraphy. In: Nuclear Medicine in Clinical Diagnosis and Treatment. Churchill Livingston, 727-735, 1994.
14. Abdel-Dayem, HM, Scott, AM, Macapinlac, HA, El-Gazzar, AH, Larson, SM. Role of Thallium-201 Chloride and Tc-99m Sestamibi in Tumor Imaging. In: Nuclear Medicine Annual. Raven Press, 181-234, 1994.
15. Abdel-Dayem, HM, Macapinlac HA, Larson, SM. The role of thallium chloride in brain tumor imaging. In: Brain: Diagnosis and Radionuclides, Current Status and Future Aspects. Mediterrea, 81-88, 1992.

Books (edited and written)

1. Bischof Delaloye A, Chiti A, Dondi M, Goh A, Macapinlac H, Mariani G, Rangarajan V, Stevens G. Ed(s) Dondi M. IAEA Human Health Series No. 9. In: Appropriate Use of FDG-PET for the Management of Cancer Patients. International Atomic Energy Agency: Vienna, Austria, 2010.
2. Macapinlac HA. Nuclear Medicine in Tumor Diagnosis and Therapy, Diagnostic Section. In: Nuclear Medicine in Clinical Diagnosis and Treatment. Churchill Livingston, 2004.

Letters to the Editor

1. Macapinlac ,HA, Larson, SM. Whole body PET in oncology. Oncology 7(7):52-55, 1993.

Manuals, Teaching Aids, Other Teaching Publications

1. Larson SM, Macapinlac HA, Shankar LK. RSP2907RC - Molecular Imaging in Oncology (2008). RSNA: Chicago, 2008.
2. Macapinlac HA. Cardinal Health: PET Champions Series Home Study CD: PET in Radiation Planning, PET in Head/Neck Cancer, PET in Lung Cancer, 2007.
3. Macapinlac HA. Educational Symposia DVD: 2005 PET-CT Imaging in Clinical Practice & PET-CT for Radiation Therapy, 2005.
4. Macapinlac HA. GE Healthcare Videotape/CD: PET Oncology Fundamentals for Reading & Referring Physicians, 2001.
5. Larson SM, Macapinlac HA, Yeung HWD, Rigo P. Clinical PET in Oncology. Williams & Wilkins, 1996.

Grant & Contract Support

Title: Evaluation of Interim FLT-PET/CT for Early Prediction of Outcome of Patients with Diffuse Large B-cell Lymphoma (DLBCL) Treated with R-CHOP
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Andrew Quon, MD
Duration: 6/1/2011 - 3/31/2015
 
Title: 18F-Fluoride PET/CT versus 99m Tc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging
Funding Source: Academy of Molecular Imaging (AMI)
Role: Principal Investigator
Duration: 6/1/2009 - 12/31/2014
 
Title: ARRA: A phase II study to test the correlation of a radiation pneumonitis imaging biomarker with clinical endpoints.
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Thomas Guerrero
Duration: 6/1/2009 - 11/30/2012
 
Title: A phase 2, open-label, proof-of-concept study to assess the ability to detect tumors and angiogenesis via the expression of alpha v beta 3 and 5 integrin receptors by (18F)AH-111585 PET imaging.
Funding Source: GE Healthcare
Role: Principal Investigator
Duration: 10/11/2007 - 2/28/2011
 
Title: Phase II Validation of 4-Dimensional Computed Tomography Derived Ventilation for Image Guided Radiotherapy of Lung Cancer
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Guerrero, Thomas M
Duration: 6/1/2007 - 5/31/2011
 
Title: Early Prediction of Pathological Response of Chemotherapy with FLT PET.
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Clifford Chao, MD
Duration: 4/1/2006 - 3/31/2008
 
Title: Program Project 2: Molecular Imaging of EGFR Expression and Activity in Targeted Therapy of Lung Cancer
Funding Source: Department of Defense (DOD)
Role: Collaborator
Principal Investigator: Waun K. Hong, MD
Duration: 2/1/2005 - 2/28/2014
 
Title: Development of Poly-L-Glutamic Acid Paclitaxel Conjugate
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Ritsuko Komaki, MD
Duration: 6/15/2002 - 6/14/2007

Last updated: 2/5/2014